Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Here is What Hedge Funds Think About Seattle Genetics, Inc. (SGEN)

Page 1 of 2

Based on the fact that hedge funds have collectively under-performed the market for several years, it would be easy to assume that their stock picks simply aren’t very good. However, our research shows this not to be the case. In fact, when it comes to their very top picks collectively, they show a strong ability to pick winning stocks. Between November 1, 2014 and October 30 of this year, less than 49% of the stocks in the S&P 500 beat the market. However, hedge funds’ top 30 stock picks from the index had a much higher success rate than this, at 63%. The returns from these 30 stocks also easily bested the broader market, at 9.5% compared to 5.2%, despite there being a few duds in there like Micron and Anadarko (even their collective wisdom isn’t perfect). The results show that there is plenty of merit to imitating the collective wisdom of top investors.

Is Seattle Genetics, Inc. (NASDAQ:SGEN) ready to rally soon? Prominent investors are buying. The number of long hedge fund bets went up by 5 lately. At the end of this article we will also compare SGEN to other stocks including Cameco Corporation (USA) (NYSE:CCJ), Michaels Companies Inc (NASDAQ:MIK), and Zillow Inc (NASDAQ:Z) to get a better sense of its popularity.

Follow Seattle Genetics Inc (NASDAQ:SGEN)
Trade (NASDAQ:SGEN) Now!

Keeping this in mind, let’s check out the new action encompassing Seattle Genetics, Inc. (NASDAQ:SGEN).

What does the smart money think about Seattle Genetics, Inc. (NASDAQ:SGEN)?

At the end of the third quarter, a total of 21 of the hedge funds tracked by Insider Monkey were bullish on this stock, a change of 31% from the previous quarter. With hedge funds’ capital changing hands, there exists an “upper tier” of key hedge fund managers who were upping their stakes significantly (or already accumulated large positions).

According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Baker Bros. Advisors, managed by Julian Baker and Felix Baker, holds the largest position in Seattle Genetics, Inc. (NASDAQ:SGEN). Baker Bros. Advisors has a $1.3893 billion position in the stock, comprising 12.8% of its 13F portfolio. On Baker Bros. Advisors’s heels is Jeremy Green of Redmile Group, with a $469.7 million position; the fund has 10.8% of its 13F portfolio invested in the stock. Some other peers that are bullish contain Ken Griffin’s Citadel Investment Group, Jerome Pfund and Michael Sjostrom’s Sectoral Asset Management and Richard Chilton’s Chilton Investment Company.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!